Question

Trastuzumab is a/an

• A. EGFR/HER 2 inhibitor
• B. Angiogenesis inhibitor
• C. EGF Receptor HER inhibitor
• D. BCR-ABL tyrosine kinase inhibitors

Answer 1

The Correct Option is A

Trastuzumab is a monoclonal antibody used in the treatment of HER2-positive breast cancer. It specifically targets the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in some breast cancer patients. By binding to the HER2 protein, trastuzumab inhibits the proliferation of cancer cells that depend on this growth signal for division and survival.

Let's analyze the options given:

1. EGFR/HER 2 inhibitor: Correct. Trastuzumab acts as a HER2 inhibitor, interfering with the signaling pathways that stimulate cell growth.
2. Angiogenesis inhibitor: Incorrect. Angiogenesis inhibitors prevent the growth of new blood vessels. Trastuzumab does not act by inhibiting angiogenesis.
3. EGF Receptor HER inhibitor: Incorrect. While "HER" is part of the HER2 receptor, this option is not specific enough. The correct term is HER2 inhibitor, specifically referring to HER2/neu.
4. BCR-ABL tyrosine kinase inhibitors: Incorrect. BCR-ABL inhibitors, such as imatinib, target a different pathway associated with chronic myeloid leukemia.

In conclusion, the correct answer is EGFR/HER 2 inhibitor as trastuzumab specifically targets and inhibits the HER2 protein.